Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian H Kushner

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Cancer Reports (Hoboken, N.J.)|May 17, 2022
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsJaume Mora, Godfrey C Chan, Daniel A Morgenstern, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pediatric Blood & Cancer|January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastomaBrian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer|November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapyShakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
International Journal of Cancer|August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastomaBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Pediatric Blood & Cancer|July 31, 2021
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastomaSanam Shahid, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastomaVictoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Cancer Reports (Hoboken, N.J.)|May 17, 2022
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse eventsJaume Mora, Godfrey C Chan, Daniel A Morgenstern, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pediatric Blood & Cancer|January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastomaBrian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer|November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapyShakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
International Journal of Cancer|August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastomaBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Pediatric Blood & Cancer|July 31, 2021
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastomaSanam Shahid, Brian H Kushner, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastomaVictoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
Pageof 11